Alfresa : Commencement of Full-Scale Operation of Home Care Delivery, a Specialized Service for Delivering Specialty Pharmaceuticals to Patients’ Homes

Translation

Notice: This document is an excerpt translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Tokyo, October 3, 2023

Alfresa Holdings Corporation

Commencement of Full-Scale Operation of Home Care Delivery, a Specialized Service

for Delivering Specialty Pharmaceuticals to Patients' Homes

Helping provide patients who need treatment for rare diseases better access

to pharmaceuticals

Consolidated subsidiary Alfresa Corporation (head office: Chiyoda Ward, Tokyo; representative

director and president: Yusuke Fukujin; hereinafter "Alfresa") has established Home Care Delivery, a service dedicated to delivering specialty pharmaceuticals to patients' homes. Alfresa has commenced services of Home Care Delivery with hemophilia drug treatments provided by CSL Behring K.K. (head office: Minato Ward, Tokyo; representative director and president: Izumi Yoshida; hereinafter "CSL Behring") as the first eligible specialty pharmaceutical.

1. Background Information and the Purpose of Establishment

Patients were forced to refrain from visiting medical institutions over concerns of infection due to the COVID-19 pandemic. As the situation continued, Alfresa launched the pilot operation of its specialized service, Home Care Delivery, to help patients who-in addition to requiring online checkups and drug administration guidance-need a safe, secure, and reliable way to have essential pharmaceuticals delivered directly to their homes.

For the pilot operation of said service, Alfresa delivered a drug to treat hemophilia manufactured by CSL Behring, which confirmed that it was possible to deliver pharmaceuticals to patients' homes while ensuring the quality of such pharmaceuticals. In light of this confirmation, Alfresa decided to embark on a full-scale operation. The launch of Home Care Delivery will not only help reduce the burden placed on patients of having to leave their homes to pick up their pharmaceuticals but also aid in alleviating the burden on medical institutions of having to manage inventory and mitigate disposal-related risks. By combining this service with online checkups and drug administration guidance, Alfresa expects that it will be able to provide a full range of medical services, from medical examinations, administration, and drug administration guidance to home delivery, to patients who need specialty pharmaceuticals.

To provide such patients with better access to these pharmaceuticals, Alfresa will work with pharmaceutical companies to expand the range of drugs covered by Home Care Delivery while also endeavoring to increase the scope of the service so that more patients and medical institutions can take advantage of it.

Note: Hemophilia is an inherited bleeding disorder caused by low levels of one of the blood

1

coagulation factors (factor VIII, factor IX) that coagulate blood upon bleeding. Patients with hemophilia who are admitted to a hospital often carry prescribed pharmaceuticals home in suitcases, placing a heavy burden on them.

2. About Home Care Delivery Overview

・ Target area: Kanto, Chubu, and Kinki regions (excluding certain parts of said regions) ・ Partner companies

Pharmaceutical company: CSL Behring K.K.

Logistics company: Yamato Transport Co., Ltd.

・ Applicable drugs: AFSTYLA (treatment for hemophilia A), IDELVION (treatment for hemophilia B)

Distribution Flow

Note: Home Care Delivery is a registered trademark of Alfresa Corporation.

About CSL Behring

CSL Behring specializes in biological products, including recombinant products, and continues to challenge the possibilities of human life, leveraging the extensive knowledge and experience it has cultivated over many years as a pioneer in plasma-derived products. CSL Behring develops innovative formulations to treat rare diseases and serious symptoms in the fields of hemophilia, immunology and rare diseases, and critical care and hemostasis, with the hope of enriching the lives of patients and their families around the world.

About the Alfresa Group

The Alfresa Group is a leader in the Japanese healthcare industry and is dedicated to making its corporate philosophy, "we create and deliver a fresh life for all," come true through a wide range of business lines, including ethical pharmaceuticals wholesaling, OTC pharmaceuticals wholesaling, pharmaceutical manufacturing, and operating dispensing pharmacies. Alfresa

2

Holdings Corporation (TSE:2784) reported consolidated revenue of ¥2.6 trillion for the fiscal year ended March 31, 2023. For more information, please see: https://www.alfresa.com/eng/

3